Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 16 | 2025 | 190 | 6.900 |
Why?
|
| Anticoagulants | 14 | 2024 | 602 | 3.420 |
Why?
|
| Thrombotic Microangiopathies | 7 | 2022 | 50 | 2.590 |
Why?
|
| Venous Thrombosis | 6 | 2024 | 171 | 2.180 |
Why?
|
| ADAMTS13 Protein | 7 | 2025 | 66 | 1.750 |
Why?
|
| Thrombosis | 5 | 2025 | 498 | 1.560 |
Why?
|
| Pulmonary Embolism | 4 | 2024 | 191 | 1.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 1265 | 1.340 |
Why?
|
| Plasma Exchange | 5 | 2025 | 84 | 1.260 |
Why?
|
| Urate Oxidase | 2 | 2020 | 16 | 1.230 |
Why?
|
| Factor Xa Inhibitors | 3 | 2024 | 59 | 1.200 |
Why?
|
| Multiple Myeloma | 3 | 2023 | 191 | 1.190 |
Why?
|
| Hyperuricemia | 2 | 2020 | 39 | 1.190 |
Why?
|
| Neoplasms | 9 | 2023 | 2964 | 1.160 |
Why?
|
| Hemorrhage | 7 | 2025 | 494 | 1.080 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 5 | 2025 | 52 | 0.940 |
Why?
|
| Data Mining | 1 | 2025 | 65 | 0.880 |
Why?
|
| Natural Language Processing | 1 | 2025 | 77 | 0.870 |
Why?
|
| Lymphoma | 2 | 2025 | 329 | 0.840 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2020 | 12 | 0.760 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2019 | 24 | 0.700 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 685 | 0.650 |
Why?
|
| Risk Factors | 17 | 2025 | 11022 | 0.640 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 546 | 0.640 |
Why?
|
| Vitamin K | 2 | 2019 | 34 | 0.640 |
Why?
|
| Blood Coagulation | 2 | 2024 | 134 | 0.620 |
Why?
|
| Rivaroxaban | 2 | 2019 | 48 | 0.620 |
Why?
|
| Thromboembolism | 2 | 2019 | 94 | 0.620 |
Why?
|
| Thalidomide | 1 | 2019 | 39 | 0.610 |
Why?
|
| Dalteparin | 1 | 2019 | 5 | 0.610 |
Why?
|
| Electronic Health Records | 2 | 2025 | 813 | 0.580 |
Why?
|
| Allopurinol | 1 | 2020 | 79 | 0.580 |
Why?
|
| Thiazoles | 1 | 2019 | 110 | 0.570 |
Why?
|
| Hospital Mortality | 2 | 2020 | 1075 | 0.570 |
Why?
|
| Gout Suppressants | 1 | 2019 | 75 | 0.560 |
Why?
|
| Pyridines | 1 | 2019 | 258 | 0.530 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 251 | 0.520 |
Why?
|
| Administration, Oral | 5 | 2020 | 700 | 0.520 |
Why?
|
| Retrospective Studies | 18 | 2024 | 17763 | 0.510 |
Why?
|
| Aged | 21 | 2025 | 21005 | 0.510 |
Why?
|
| Middle Aged | 22 | 2025 | 28553 | 0.500 |
Why?
|
| Humans | 47 | 2025 | 130959 | 0.500 |
Why?
|
| Incidence | 6 | 2025 | 3360 | 0.480 |
Why?
|
| Male | 30 | 2025 | 64765 | 0.460 |
Why?
|
| Transplantation, Homologous | 4 | 2022 | 674 | 0.460 |
Why?
|
| Risk Assessment | 8 | 2025 | 3717 | 0.450 |
Why?
|
| Female | 30 | 2025 | 70720 | 0.440 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 296 | 0.430 |
Why?
|
| Adult | 20 | 2025 | 31296 | 0.410 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1796 | 0.390 |
Why?
|
| Registries | 1 | 2019 | 1608 | 0.370 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 6797 | 0.370 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 735 | 0.360 |
Why?
|
| Cohort Studies | 9 | 2023 | 5100 | 0.350 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 125 | 0.290 |
Why?
|
| Uric Acid | 2 | 2020 | 110 | 0.290 |
Why?
|
| Secondary Prevention | 2 | 2021 | 219 | 0.280 |
Why?
|
| Hemostasis | 2 | 2025 | 76 | 0.270 |
Why?
|
| Immunologic Factors | 2 | 2019 | 188 | 0.270 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2939 | 0.260 |
Why?
|
| Warfarin | 2 | 2019 | 123 | 0.260 |
Why?
|
| Propensity Score | 2 | 2020 | 270 | 0.250 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 313 | 0.240 |
Why?
|
| Inpatients | 3 | 2025 | 549 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 3059 | 0.230 |
Why?
|
| Anemia, Hemolytic | 1 | 2025 | 30 | 0.230 |
Why?
|
| Prognosis | 5 | 2025 | 4950 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2849 | 0.210 |
Why?
|
| Treatment Outcome | 8 | 2020 | 12956 | 0.200 |
Why?
|
| Heparin | 1 | 2024 | 205 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1079 | 0.190 |
Why?
|
| Rituximab | 2 | 2025 | 173 | 0.190 |
Why?
|
| Central Venous Catheters | 1 | 2023 | 51 | 0.190 |
Why?
|
| United States | 7 | 2025 | 11852 | 0.190 |
Why?
|
| Hospitalization | 2 | 2024 | 1935 | 0.170 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 1418 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 388 | 0.170 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2021 | 34 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2025 | 379 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 351 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1129 | 0.160 |
Why?
|
| Recurrence | 2 | 2021 | 1481 | 0.160 |
Why?
|
| Twins | 1 | 2020 | 70 | 0.160 |
Why?
|
| Unrelated Donors | 1 | 2020 | 71 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 158 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 76 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 31 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 161 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 144 | 0.140 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 132 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2019 | 61 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 190 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 164 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 1248 | 0.140 |
Why?
|
| Biomarkers | 2 | 2017 | 3403 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 153 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 346 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 230 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2021 | 384 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2020 | 1229 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1361 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 511 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 492 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 563 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 439 | 0.120 |
Why?
|
| Phenotype | 1 | 2025 | 4484 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2024 | 999 | 0.110 |
Why?
|
| Aminocaproic Acid | 1 | 2015 | 4 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1353 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2015 | 83 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 659 | 0.110 |
Why?
|
| Survival Rate | 3 | 2025 | 2145 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2019 | 1225 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2019 | 764 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1155 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 220 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2025 | 309 | 0.100 |
Why?
|
| Body Weight | 1 | 2017 | 988 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 955 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2313 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 692 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1550 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1793 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1701 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 6491 | 0.080 |
Why?
|
| Sex Factors | 2 | 2025 | 1336 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6147 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 901 | 0.070 |
Why?
|
| Child | 3 | 2025 | 26220 | 0.070 |
Why?
|
| Age Factors | 2 | 2025 | 2851 | 0.060 |
Why?
|
| Single-Domain Antibodies | 1 | 2025 | 8 | 0.060 |
Why?
|
| Acute Disease | 2 | 2020 | 1153 | 0.060 |
Why?
|
| Platelet Count | 1 | 2025 | 139 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2025 | 60 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2025 | 119 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2024 | 55 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2025 | 192 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2025 | 597 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2025 | 343 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 160 | 0.050 |
Why?
|
| Young Adult | 3 | 2025 | 10016 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 317 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2025 | 439 | 0.050 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 19 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 893 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 109 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2024 | 285 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 436 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 28 | 0.040 |
Why?
|
| Dabigatran | 1 | 2019 | 26 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 191 | 0.040 |
Why?
|
| Antithrombins | 1 | 2019 | 49 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 219 | 0.040 |
Why?
|
| Blood Component Removal | 1 | 2019 | 35 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 149 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 208 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1842 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 682 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1619 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2019 | 355 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 931 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 500 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5246 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 734 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1815 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3417 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 167 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2123 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1391 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 847 | 0.020 |
Why?
|
| Heart Failure | 1 | 2024 | 2322 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1399 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13332 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 15018 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 20817 | 0.010 |
Why?
|